Aspen Neuroscience Prices $140.6M IPO at $15 a Share, Trades Friday
Summary
Aspen Neuroscience priced its initial public offering at $15.00 a share, selling 9,375,000 shares for gross proceeds of roughly $140.6 million before fees. Underwriters hold a 30-day option on up to 1,406,250 more shares, which would add about $21 million if fully exercised. The Parkinson's disease cell-therapy developer lists on the Nasdaq Global Select Market under ASPE, with trading expected to begin October 30 and the deal set to close November 2. Leerink, Piper Sandler, Stifel, UBS and Oppenheimer are joint bookrunners. The raise funds clinical development of the lead candidate sasineprocel, an autologous iPSC-derived single-dose therapy for PD. First-day trading will set the real valuation; the pricing itself is the key reference point for anyone taking a position at the open.
This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.